Effect of vitamin D supplementation in combination with weight loss diet on lipid profile and sirtuin 1 in obese subjects with vitamin D deficiency: a double blind randomized clinical trial.
Journal: 2019/November - Health Promotion Perspectives
ISSN: 2228-6497
Abstract:
Background: Due to inconsistent evidence regarding the potential role of vitamin D on lipid profile and sirtuin 1 (SIRT-1), this study was designed to investigate the effect of vitamin D supplementation in combination with weight loss diet on lipid profile and SIRT-1 in obese subjects with vitamin D deficiency. Methods: Forty-four obese subjects with vitamin D deficiency were randomly assigned in a randomized clinical trial to receive either a weight reduction diet supplemented with 50000IU vitamin D3 pearl (n = 22) or placebo (n = 22) once weekly for 12 weeks. Changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) and SIRT-1 were the primary outcomes. Secondary outcomes were changes in body mass index (BMI), 25(OH) D and parathyroid hormone (PTH). Physical activity and dietary intakes were also assessed. Results: During the intervention, PTH (mean difference, -33.36; 95% CI: -49.15 to -17.57;P<0.001) and LDL-C (mean difference, -15.91; 95% CI: -21.76 to -10.07; P<0.001) decreased and 25(OH) D (mean difference, 36.44; 95% CI: 29.05 to 43.83; P<0.001) increased significantly in the vitamin D group. BMI (mean differences: -2.40; 95% CI: [-2.92 to-1.88] in vitamin D group and mean differences: -1.90; 95% CI [-6.58 to -3.01] in placebo group, P<0.05 for both groups), TC (mean difference,-21.31; 95% CI: -27.24 to -15.38; P<0.001 in vitamin D group and mean difference, -12.54; 95% CI: -19.02 to -6.06; P<0.001 in placebo group) and TG (mean difference,-21.31; 95% CI: -27.24 to -15.38; P<0.001in vitamin D group and mean difference, -12.54; 95% CI: -19.02 to -6.06; P<0.001 in placebo group) decreased and SIRT-1(mean difference, 3.95; 95% CI: 1.18 to 6.73; P=0.007in vitamin D group and mean difference,1.91; 95% CI: 0.31 to 3.63 in placebo group, P=0.022) increase significantly in both group. At end of the study, 25(OH) D and PTH showed significant differences in between-group analyses(P<0.05). No significant difference was detected for HDL-C in within and between groups. Conclusion: This study gives no support for any beneficial effect of vitamin D supplementation on lipid profile and SIRT-1 in obese subjects with vitamin D deficiency.
Relations:
Content
References
(39)
Diseases
(3)
Conditions
(2)
Drugs
(1)
Chemicals
(3)
Genes
(3)
Processes
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Health Promot Perspect 9(4): 263-269

Effect of vitamin D supplementation in combination with weight loss diet on lipid profile and sirtuin 1 in obese subjects with vitamin D deficiency: a double blind randomized clinical trial

Student Research Committee, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Nutritional Biochemistry, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Social Determinant of Health Research Center, Faculty of Nutrition &amp; Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Corresponding Author: Mehrangiz Ebrahimi- Mameghani, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Attar Neyshaboori Av., Golghasht St., Tabriz, Iran. Tel: +98- 04133357581, Fax: 0098-0411-3344731, Email: ri.ca.demzbt@inagamamimiharbe
Received 2019 Jun 2; Accepted 2019 Aug 22.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Due to inconsistent evidence regarding the potential role of vitamin D on lipid profile and sirtuin 1 (SIRT-1), this study was designed to investigate the effect of vitamin D supplementation in combination with weight loss diet on lipid profile and SIRT-1 in obese subjects with vitamin D deficiency.

Methods: Forty-four obese subjects with vitamin D deficiency were randomly assigned in a randomized clinical trial to receive either a weight reduction diet supplemented with 50000IU vitamin D3 pearl (n = 22) or placebo (n = 22) once weekly for 12 weeks. Changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) and SIRT-1 were the primary outcomes. Secondary outcomes were changes in body mass index (BMI), 25(OH) D and parathyroid hormone (PTH). Physical activity and dietary intakes were also assessed.

Results: During the intervention, PTH (mean difference, -33.36; 95% CI: -49.15 to -17.57;P<0.001) and LDL-C (mean difference, -15.91; 95% CI: -21.76 to -10.07; P<0.001) decreased and 25(OH) D (mean difference, 36.44; 95% CI: 29.05 to 43.83; P<0.001) increased significantly in the vitamin D group. BMI (mean differences: -2.40; 95% CI: [-2.92 to-1.88] in vitamin D group and mean differences: -1.90; 95% CI [-6.58 to -3.01] in placebo group, P<0.05 for both groups), TC (mean difference,-21.31; 95% CI: -27.24 to -15.38; P<0.001 in vitamin D group and mean difference, -12.54; 95% CI: -19.02 to -6.06; P<0.001 in placebo group) and TG (mean difference,-21.31; 95% CI: -27.24 to -15.38; P<0.001in vitamin D group and mean difference, -12.54; 95% CI: -19.02 to -6.06; P<0.001 in placebo group) decreased and SIRT-1(mean difference, 3.95; 95% CI: 1.18 to 6.73; P=0.007in vitamin D group and mean difference,1.91; 95% CI: 0.31 to 3.63 in placebo group, P=0.022) increase significantly in both group. At end of the study, 25(OH) D and PTH showed significant differences in between-group analyses(P<0.05). No significant difference was detected for HDL-C in within and between groups.

Conclusion: This study gives no support for any beneficial effect of vitamin D supplementation on lipid profile and SIRT-1 in obese subjects with vitamin D deficiency.

Keywords: Lipid profile, Obesity, Sirtuin1, Vitamin D, Weight loss diet
Abstract

HEPA, health enhancing physical activity.

Data presented as mean ± standard deviation for quantitative variable and No. (%) for categorical variables.

P value for independent sample t test.

P value for chi-square test.

Study flow diagram.

BMI before and after intervention in vitamin D and placebo groups.

* Mean ± SD.

P value for paired t test.

P value for ANCOVA; adjusted for baseline values.

PTH, Parathyroid hormone; TC, Total cholesterol; LDL-C, low-density lipoprotein cholesterol, TG, triglyceride; HDL-C, low high-density lipoprotein cholesterol, SIRT-1: Sirtuin 1.

* All values are mean ± SD.

P value for Paired t test.

P value for ANCOVA; adjusted for baseline values, serum calcium concentrations, changes on weight, dietary intake of vitamin D and sun exposure.

Notes

Citation: Aliashrafi S, Rafie-Arefhosseini S, Lotfi-Dizaji L, Ebrahimi-Mameghani M. Effect of vitamin D supplementation in combination with weight loss diet on lipid profile and sirtuin 1 in obese subjects with vitamin D deficiency: a double blind randomized clinical trial. Health Promot Perspect. 2019;9(4):263-269. doi: 10.15171/hpp.2019.36.

Notes

References

  • 1. Meldrum DR, Morris MA, Gambone JCObesity pandemic: causes, consequences, and solutions—but do wehave the will? Fertil Steril. 2017;107(4):833–9. doi: 10.1016/j.fertnstert.2017.02.104.] [[PubMed][Google Scholar]
  • 2. Chooi YC, Ding C, Magkos FThe epidemiology of obesity. Metabolism. 2019;92:6–10. doi: 10.1016/j.metabol.2018.09.005.] [[PubMed][Google Scholar]
  • 3. Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med. 1993;153(9):1093–103.[PubMed]
  • 4. Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck GRole of extracellular matrix remodelling in adipose tissue pathophysiology: relevance in the development of obesity. Histol Histopathol. 2012;27(12):1515–28.[PubMed][Google Scholar]
  • 5. Ortega FB, Lavie CJ, Blair SNObesity and cardiovascular disease. Circ Res. 2016;27:1752–70. doi: 10.1161/CIRCRESAHA.115.306883.] [[PubMed][Google Scholar]
  • 6. Zhang D, Wang G, Fang J, Mercado CHyperlipidemia and medical expenditures by cardiovascular disease status in US adults. Med Care. 2017;55(1):4–11.[PubMed][Google Scholar]
  • 7. Nelson RHHyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195–211. doi: 10.1016/j.pop.2012.11.003.] [[Google Scholar]
  • 8. Karr SEpidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139–48.[PubMed][Google Scholar]
  • 9. Fiorino E, Giudici M, Ferrari A, Mitro N, Caruso D, De Fabiani E. et al. The sirtuin class of histone deacetylases: regulation and roles in lipid metabolism. IUBMB Life. 2014;66(2):89–99. doi: 10.1002/iub.1246.] [[PubMed]
  • 10. Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO. et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92(3):1479–514. doi: 10.1152/physrev.00022.2011.] [
  • 11. Mariani S, Di Rocco G, Toietta G, Russo MA, Petrangeli E, Salvatori LSirtuins 1-7 expression in human adipose-derived stem cells from subcutaneous and visceral fat depots: influence of obesity and hypoxia. Endocrine. 2017;57(3):455–63. doi: 10.1007/s12020-016-1170-8.] [[PubMed][Google Scholar]
  • 12. Liu HX, Wang YM, Hu JP, Huang LY, Fang NYAdipocyte differentiation is regulated by mitochondrial trifunctional protein α-subunit via sirtuin 1. Exp Cell Res. 2017;357(2):271–81. doi: 10.1016/j.yexcr.2017.05.020.] [[PubMed][Google Scholar]
  • 13. Ye X, Li M, Hou T, Gao T, Zhu WG, Yang YSirtuins in glucose and lipid metabolism. Oncotarget. 2017;8(1):1845–59. doi: 10.18632/oncotarget.] [[Google Scholar]
  • 14. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente LSIRT-1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28(1):91–106.[PubMed][Google Scholar]
  • 15. Xu S, Bai P, Jin ZGSirtuins in Cardiovascular Health and Diseases. Trends Endocrinol Metab. 2016;27(10):677–78. doi: 10.1016/j.tem.2016.07.004.] [[Google Scholar]
  • 16. Nair R, Maseeh AVitamin D: the “sunshine” vitamin. J Pharmacol Pharmacother. 2012;3(2):118–26. doi: 10.4103/0976-500X.95506.] [[Google Scholar]
  • 17. Holick MFVitamin D deficiency. N Engl J Med. 2007;357(3):266–81.[PubMed][Google Scholar]
  • 18. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11. doi: 10.1161/CIRCULATIONAHA.107.706127.] [
  • 19. Wang Y, Si S, Liu J, Wang Z, Jia H, Feng K. et al. The Associations of serum lipids with vitamin D status. PLoS One. 2016;11(10):e0165157. doi: 10.1371/journal.pone.0165157.] [
  • 20. Al Mheid I, Quyyumi AAVitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol. 2017;70(1):89–100. doi: 10.1016/j.jacc.2017.05.031.] [[PubMed][Google Scholar]
  • 21. Polidoro L, Properzi G, Marampon F, Gravina G, Festuccia C, Di Cesare E. et al. Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res. 2013;6(2):221–31. doi: 10.1007/s12265-012-9436-x.] [[PubMed]
  • 22. Chang E, Kim YVitamin D decreases adipocyte lipid storage and increases NAD-SIRT-1 pathway in 3T3-L1 adipocytes. Nutrition. 2016;32(6):702–8. doi: 10.1016/j.nut.2015.12.032.] [[PubMed][Google Scholar]
  • 23. Shetty PEnergy requirements of adults. Public Health Nutr. 2005;8(7a):994–1009.[PubMed][Google Scholar]
  • 24. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA. et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009;69(3):967–75. doi: 10.1158/0008-5472.CAN-08-2307.] [
  • 25. Deurenberg P, Weststrate JA, Seidell JCBody mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991;65(2):105–14.[PubMed][Google Scholar]
  • 26. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE. et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95.[PubMed]
  • 27. Salekzamani S, Mehralizadeh H, Ghezel A, Salekzamani Y, Jafarabadi MA, Bavil AS. et al. Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial. J Endocrinol Invest. 2016;39(11):1303–13.[PubMed]
  • 28. Warnick GR, Knopp RH, Fitzpatrick V, Branson LEstimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990;36(1):15–9.[PubMed][Google Scholar]
  • 29. Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC. et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23(4):591–601.
  • 30. Jorde R, Grimnes GVitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12. doi: 10.1016/j.plipres.2011.05.001.] [[PubMed][Google Scholar]
  • 31. Kubiak J, Thorsby PM, Kamycheva E, Jorde RVitamin D supplementation does not improve CVD risk factors in vitamin D-insufficient subjects. Endocr Connect. 2018;7(6):840–9. doi: 10.1530/EC-18-0144.] [[Google Scholar]
  • 32. Wamberg L, Kampmann U, Stødkilde-Jørgensen H, Rejnmark L, Pedersen SB, Richelsen BEffects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels - results from a randomized trial. Eur J Intern Med. 2013;24(7):644–9. doi: 10.1016/j.ejim.2013.03.005.] [[PubMed][Google Scholar]
  • 33. Jorde R, Sneve M, Torjesen P, Figenschau YNo improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267(5):462–72. doi: 10.1111/j.1365-2796.2009.02181.x.] [[PubMed][Google Scholar]
  • 34. Ostadmohammadi V, Milajerdi A, Ghayour-Mobarhan M, Ferns G, Taghizadeh M, Badehnoosh B. et al. The effects of vitamin D supplementation on glycemic control, lipid profiles and C-reactive protein among patients with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2019;25(2):201–210. doi: 10.2174/1381612825666190308152943.] [[PubMed]
  • 35. Mohamad MI, El-Sherbeny EE, Bekhet MMThe effect of vitamin d supplementation on glycemic control and lipid profile in patients with type 2 diabetes --mellitus. J Am Coll Nutr. 2016;35(5):399–404. doi: 10.1080/07315724.2015.1026427.] [[PubMed][Google Scholar]
  • 36. Ramiro-Lozano JM, Calvo-Romero JMEffects on lipid profile of supplementation with vitamin D in type 2 diabetic patients with vitamin D deficiency. Ther Adv Endocrinol Metab. 2015;6(6):245–8. doi: 10.1177/2042018815599874.] [[Google Scholar]
  • 37. Crujeiras A, Parra D, Goyenechea E, Martínez JSirtuin gene expression in human mononuclear cells is modulated by caloric restriction. Eur J Clin Invest. 2008;38(9):672–8. doi: 10.1111/j.1365-2362.2008.01998.x.] [[PubMed][Google Scholar]
  • 38. Chang E, Kim YVitamin D insufficiency exacerbates adipose tissue macrophage infiltration and decreases AMPK/SIRT1 activity in obese rats. Nutrients. 2017;9(4):E338. doi: 10.3390/nu9040338.] [[Google Scholar]
  • 39. Ruiz-Ojeda FJ, Anguita-Ruiz A, Leis R Aguilera CMGenetic factors and molecular mechanisms of vitamin D and obesity relationship. Ann Nutr Metab. 2018;73(2):89–99. doi: 10.1159/000490669.] [[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.